Cannabis and Cardiovascular Health: What Research Shows About Heart Risks

Executive Summary

Emerging research reveals a complex relationship between cannabis use and cardiovascular health, with cardiologists urging caution despite mixed evidence. As cannabis legalization expands across the United States, medical professionals increasingly confront questions about marijuana's effects on heart health, blood pressure, and stroke risk. Recent studies published between 2023 and 2026 demonstrate both potential cardiovascular risks—including increased heart attack incidence among daily users and elevated stroke risk in younger adults—and possible therapeutic applications for certain heart conditions. The American Heart Association updated its position in 2024, acknowledging insufficient evidence to recommend cannabis for cardiovascular disease while highlighting concerns about smoking as a delivery method. With approximately 48.2 million Americans reporting past-year cannabis use according to 2025 federal data, and medical marijuana programs operating in 38 states, understanding the cardiovascular implications has become a public health priority affecting patients, physicians, insurers, and policymakers navigating the intersection of expanding access and emerging clinical evidence.

Why This Matters

The cardiovascular implications of cannabis use affect millions of patients, billions in healthcare costs, and the clinical decision-making of cardiologists nationwide. Cardiovascular disease remains the leading cause of death in the United States, accounting for approximately 695,000 deaths annually according to the Centers for Disease Control and Prevention. As cannabis use becomes normalized through state-level legalization, the potential for population-level cardiovascular impacts grows substantially. Medical marijuana patients with pre-existing heart conditions represent a particularly vulnerable population. An estimated 6.2 million Americans live with heart failure, while 20.1 million adults have coronary artery disease. Many of these patients seek cannabis for pain management, sleep disorders, or anxiety—conditions frequently comorbid with cardiovascular disease. Cardiologists report increasing frequency of patient inquiries about cannabis safety, yet evidence-based guidance remains limited. The financial stakes are considerable. Cardiovascular disease costs the United States approximately $239 billion annually in healthcare services, medications, and lost productivity. If cannabis use contributes to increased cardiovascular events, the economic burden could expand significantly. Conversely, if certain cannabinoids demonstrate therapeutic cardiovascular properties, the market opportunity for pharmaceutical development could reach billions of dollars. Insurance companies and employers face coverage decisions without clear clinical guidelines. Workers' compensation carriers in states with medical marijuana programs must determine whether to cover cannabis for injured workers with cardiovascular risk factors. Health insurers evaluate whether to exclude coverage for cannabis-related cardiovascular events, while life insurance underwriters increasingly incorporate cannabis use into risk assessments. State regulators confront policy questions about patient education requirements, physician training standards, and product labeling for cardiovascular warnings. The Food and Drug Administration faces pressure to establish research pathways that can generate definitive cardiovascular safety data while navigating federal prohibition under the Controlled Substances Act.

Background and History

Scientific investigation of cannabis and cardiovascular health spans more than five decades, evolving from case reports to large-scale epidemiological studies.

Early Case Reports (1970s-1990s)

The medical literature first documented potential cardiovascular effects of cannabis in the early 1970s. Researchers observed acute increases in heart rate and blood pressure following cannabis consumption, with heart rate elevations of 20-50 beats per minute documented in controlled studies. A 1975 study published in the New England Journal of Medicine reported decreased exercise tolerance in patients with angina after marijuana smoking, suggesting potential risks for individuals with coronary artery disease. Throughout the 1980s, case reports emerged linking cannabis use to acute cardiovascular events in young adults. A 1982 case series described myocardial infarction in otherwise healthy young men following marijuana use, though establishing causation remained challenging given the rarity of such events and potential confounding factors including tobacco use.

Mechanistic Research (1990s-2000s)

The discovery of the endocannabinoid system in the 1990s revolutionized understanding of how cannabis compounds interact with human physiology. Researchers identified cannabinoid receptors CB1 and CB2 throughout the cardiovascular system, including in cardiac tissue, blood vessels, and atherosclerotic plaques. This discovery suggested biological plausibility for both adverse and therapeutic cardiovascular effects. Studies in the late 1990s and early 2000s demonstrated that THC activates CB1 receptors, triggering sympathetic nervous system activation that increases heart rate and cardiac output while decreasing peripheral vascular resistance. Research published in 2001 showed that cannabis smoking produces carboxyhemoglobin levels similar to tobacco smoking, potentially reducing oxygen delivery to cardiac tissue. Simultaneously, laboratory research identified potential cardioprotective properties of certain cannabinoids. A 2003 study in the Journal of Molecular Medicine found that CBD reduced infarct size in animal models of heart attack, suggesting anti-inflammatory and antioxidant mechanisms that might protect cardiac tissue.

Population Studies Emerge (2010-2020)

The 2010s brought larger epidemiological investigations as cannabis use increased and data sources improved. A 2013 study using the National Health and Nutrition Examination Survey found associations between marijuana use and increased prevalence of cardiovascular disease, though researchers acknowledged limitations in establishing causation from cross-sectional data. The American Heart Association issued its first scientific statement on marijuana and cardiovascular health in 2014, concluding that evidence suggested potential risks but remained insufficient for definitive recommendations. The statement noted that marijuana smoking delivers many of the same cardiovascular toxins as tobacco smoke. A pivotal 2017 study published in the Journal of the American College of Cardiology analyzed data from 1.5 million hospitalizations, finding that cannabis use disorder was associated with increased risk of stroke, heart failure, and sudden cardiac death, particularly among young adults. The study sparked debate about whether associations reflected causation or confounding by tobacco use and other risk factors. Research published in 2019 using the Behavioral Risk Factor Surveillance System found that daily marijuana users had higher rates of heart attack compared to non-users, with risk increasing with frequency of use. However, the study relied on self-reported data and could not control for all potential confounders.

Recent Developments (2021-2026)

The period from 2021 to 2026 produced increasingly sophisticated research attempting to disentangle cannabis effects from confounding variables. A 2022 study in the European Heart Journal followed 135,000 participants for a median of 11 years, finding that regular cannabis use was associated with a 25% increased risk of coronary heart disease after adjusting for tobacco smoking and other cardiovascular risk factors. The American Heart Association updated its scientific statement in November 2024, incorporating new evidence while maintaining that insufficient data exists to recommend cannabis for cardiovascular conditions. The updated statement emphasized concerns about high-potency THC products and synthetic cannabinoids while acknowledging potential therapeutic applications of CBD that require further investigation. A landmark 2025 study published in JAMA Cardiology utilized Mendelian randomization—a genetic epidemiology method that reduces confounding—to examine causal relationships between cannabis use and cardiovascular outcomes. The study found genetic variants associated with cannabis use were also associated with increased coronary artery disease risk, providing stronger evidence for potential causal relationships than previous observational studies. In early 2026, the National Institutes of Health announced a $45 million research initiative to study cardiovascular effects of cannabis, representing the largest federal investment in this research area to date. The initiative includes randomized controlled trials examining CBD for heart failure and observational studies tracking cardiovascular outcomes in medical marijuana patients.

Key Players

American Heart Association

The American Heart Association has emerged as the leading medical organization addressing cannabis and cardiovascular health. The organization published scientific statements in 2014 and 2024 synthesizing available evidence and providing guidance to clinicians. The AHA's position emphasizes that smoking any substance, including cannabis, delivers harmful cardiovascular toxins and that insufficient evidence exists to recommend marijuana for cardiovascular disease treatment. The organization advocates for increased research funding and improved data collection on cardiovascular outcomes in cannabis users.

National Institutes of Health

The National Heart, Lung, and Blood Institute, part of the NIH, funds the majority of federally-supported research on cannabis and cardiovascular health. The institute launched its cardiovascular cannabis research initiative in 2026, supporting studies at institutions including Johns Hopkins University, University of California San Francisco, and Massachusetts General Hospital. NIH researchers face ongoing challenges conducting cannabis research due to federal prohibition and Drug Enforcement Administration restrictions on research-grade cannabis access.

Food and Drug Administration

The FDA regulates cannabis-derived pharmaceuticals and evaluates cardiovascular safety data for drug approval. The agency approved Epidiolex, a CBD-based medication for epilepsy, in 2018 after reviewing cardiovascular safety data from clinical trials. The FDA has issued warning letters to companies making unsubstantiated cardiovascular health claims about CBD products. The agency's position is that cannabis and cannabis-derived compounds require rigorous clinical trials demonstrating safety and efficacy before cardiovascular therapeutic claims can be made.

Drug Enforcement Administration

The DEA maintains cannabis as a Schedule I controlled substance under 21 U.S.C. § 812, classifying it as having no accepted medical use and high abuse potential. This classification creates barriers to cardiovascular research by requiring researchers to obtain special licenses and limiting access to research-grade cannabis. The DEA announced in May 2024 that it was initiating rulemaking to reschedule cannabis to Schedule III, which could facilitate expanded cardiovascular research, though the process remained ongoing as of July 2026.

State Medical Boards

Medical boards in states with cannabis programs establish standards for physician recommendations and patient education. California's Medical Board requires physicians recommending cannabis to patients with cardiovascular disease to document discussions of potential risks. New York mandates that medical marijuana patients with heart conditions receive written information about cardiovascular effects. Ohio requires cardiologists who recommend medical marijuana to complete continuing education on cannabis pharmacology and cardiovascular interactions.

Major Medical Cannabis Operators

Multi-state operators including Curaleaf, Green Thumb Industries, and Trulieve have established medical advisory boards that include cardiologists. These companies fund patient education initiatives and support cardiovascular research. Curaleaf announced a partnership with Mount Sinai Hospital in 2025 to study cardiovascular outcomes in medical cannabis patients. The companies face potential liability exposure if cardiovascular harms are definitively established and they failed to provide adequate warnings.

Medical and Scientific Evidence

Current evidence reveals both potential cardiovascular risks and possible therapeutic applications, with significant knowledge gaps remaining.

Acute Cardiovascular Effects

Cannabis consumption produces immediate cardiovascular changes that are well-documented. THC activates the sympathetic nervous system, increasing heart rate by 20-100% within minutes of use. This effect typically lasts 2-3 hours and is dose-dependent. Blood pressure responses are more variable—cannabis can cause initial increases followed by decreases as users develop tolerance. For individuals with stable cardiovascular disease, these acute effects may trigger symptoms. A 2023 study found that cannabis use within one hour before physical exertion increased the risk of exercise-induced angina in patients with coronary artery disease. The mechanism involves increased myocardial oxygen demand from elevated heart rate combined with potentially reduced oxygen delivery from carboxyhemoglobin. Research has identified a potential "trigger period" in the first hour after cannabis use when heart attack risk may be elevated. A 2021 analysis estimated that the risk of myocardial infarction is 4.8 times higher in the 60 minutes following marijuana use compared to baseline, though the absolute risk remains low for individuals without pre-existing cardiovascular disease.

Chronic Use and Cardiovascular Disease Risk

Long-term cardiovascular effects of regular cannabis use remain contested. A 2024 meta-analysis of 23 observational studies found that regular cannabis use was associated with a 25% increased risk of coronary artery disease, 35% increased risk of stroke, and 55% increased risk of heart failure compared to non-use. However, the analysis acknowledged significant heterogeneity between studies and potential residual confounding from tobacco use, which remains highly correlated with cannabis use. Studies specifically examining cannabis-only users (excluding tobacco smokers) show more modest associations. A 2025 analysis restricted to never-tobacco users found a 15% increased coronary artery disease risk among daily cannabis users, suggesting that some but not all of the cardiovascular risk observed in mixed populations may be attributable to cannabis itself. Stroke risk appears particularly elevated in younger cannabis users. Research published in 2023 found that adults aged 18-44 who used cannabis daily had more than double the stroke risk of non-users, with ischemic stroke being the predominant type. Proposed mechanisms include cannabis-induced vasospasm, arterial wall changes, and increased thrombosis risk.

Arrhythmia and Sudden Cardiac Death

Case reports and case series have documented various arrhythmias associated with cannabis use, including atrial fibrillation, ventricular tachycardia, and sudden cardiac arrest. A 2022 study using the Danish national health registry found that cannabis use disorder was associated with a 2.5-fold increased risk of atrial fibrillation in individuals under age 50. The relationship between cannabis and sudden cardiac death remains unclear. While case reports describe young adults experiencing sudden death temporally related to cannabis use, establishing causation is challenging. A 2024 autopsy study found THC metabolites in 12% of sudden cardiac death cases among individuals under 40, but the significance of this finding is debated given increasing background prevalence of cannabis use.

Potential Therapeutic Applications

Despite concerns about THC-related cardiovascular risks, research suggests certain cannabinoids may have therapeutic properties. CBD has demonstrated anti-inflammatory, antioxidant, and vasodilatory effects in laboratory and animal studies. A 2023 clinical trial found that high-dose CBD (600mg daily) reduced blood pressure and improved endothelial function in patients with hypertension, though the study was small and short-term. Research published in 2025 examined CBD for heart failure with preserved ejection fraction, a condition with limited treatment options. The randomized controlled trial of 120 patients found that CBD improved exercise capacity and quality of life measures over 12 weeks, though it did not significantly affect the primary endpoint of NT-proBNP levels, a biomarker of heart failure severity. Some researchers have investigated whether cannabinoids might reduce atherosclerosis progression. A 2024 animal study found that low-dose THC reduced atherosclerotic plaque formation in mice, potentially through anti-inflammatory mechanisms. However, translating these findings to humans remains speculative.

Delivery Method Considerations

Cardiovascular effects vary substantially by consumption method. Smoking cannabis delivers combustion byproducts including carbon monoxide, particulate matter, and polycyclic aromatic hydrocarbons—all established cardiovascular toxins. A 2023 study found that regular cannabis smoking produced endothelial dysfunction similar to tobacco smoking, measured by flow-mediated dilation. Vaporization reduces but does not eliminate exposure to harmful compounds. Research published in 2024 found that vaporized cannabis still produced measurable carbon monoxide and particulate matter, though at lower levels than smoking. The cardiovascular implications of long-term vaporizer use remain understudied. Edible cannabis products avoid inhalation-related harms but produce different pharmacokinetic profiles with delayed onset and prolonged duration of effects. A 2025 study suggested that edibles may produce less acute cardiovascular stress than smoking, though comparative cardiovascular outcome data is lacking.

Clinical Guidance and Practice

Cardiologists face challenging clinical decisions regarding cannabis use in patients with cardiovascular disease, operating with limited evidence-based guidance. The American College of Cardiology published clinical guidance in 2025 recommending that cardiologists routinely ask patients about cannabis use during cardiovascular risk assessment. The guidance suggests that patients with established cardiovascular disease, particularly coronary artery disease or heart failure, should be counseled about potential risks of cannabis use, especially smoked forms. For patients considering medical marijuana, the ACC guidance recommends shared decision-making discussions that include: documentation of the condition being treated, consideration of evidence-based alternatives, discussion of cardiovascular risks based on individual risk factors, and recommendation of non-smoked delivery methods if cannabis use proceeds. Several academic medical centers have developed institutional protocols. Massachusetts General Hospital's cardiology department implemented a cannabis screening and counseling protocol in 2024 that includes standardized patient education materials and documentation templates. The protocol recommends against cannabis use in patients with recent myocardial infarction, unstable angina, decompensated heart failure, or uncontrolled arrhythmias. Cleveland Clinic cardiologists published a case-based approach in 2025 suggesting risk stratification: patients at low cardiovascular risk who use cannabis occasionally likely face minimal incremental risk, while patients with multiple cardiovascular risk factors or established disease who use cannabis daily may face meaningful risk that should inform treatment discussions. Medication interactions present additional clinical considerations. Cannabis may interact with anticoagulants including warfarin, potentially affecting INR levels. A 2024 pharmacokinetic study found that CBD inhibits CYP2C9 and CYP3A4 enzymes, potentially increasing levels of medications metabolized by these pathways, including some statins and antiplatelet agents.

State-by-State Medical Marijuana and Cardiovascular Considerations

States with medical marijuana programs vary widely in their approach to cardiovascular conditions as qualifying conditions and patient safety requirements.

California

California's medical marijuana program, established in 1996 under the Compassionate Use Act, does not list specific qualifying conditions, allowing physicians broad discretion. The Medical Board of California issued guidance in 2023 requiring physicians to document cardiovascular risk discussions for patients with known heart disease. California does not mandate specific cardiovascular warnings on product labels, though some dispensaries voluntarily provide educational materials.

Colorado

Colorado's medical marijuana program includes chronic pain as a qualifying condition but not cardiovascular disease specifically. The Colorado Department of Public Health and Environment published a fact sheet in 2024 on cannabis and heart health, noting that smoking marijuana may harm cardiovascular health. Colorado requires medical marijuana physicians to complete continuing education that includes cardiovascular effects of cannabis.

Florida

Florida's medical marijuana program, established by constitutional amendment in 2016, includes chronic nonmalignant pain as a qualifying condition. The Florida Department of Health requires physicians to review a patient's controlled substance prescription history and assess for drug abuse risk, but does not mandate specific cardiovascular risk screening. Florida law prohibits smoking medical marijuana, though vaporization is permitted—a restriction partially motivated by respiratory and cardiovascular health concerns.

Illinois

Illinois includes specific cardiovascular conditions among its 55+ qualifying conditions for medical marijuana, though the program does not list heart disease itself. The Illinois Department of Public Health requires dispensaries to provide educational materials on health risks, including cardiovascular effects. Illinois permits home cultivation for medical patients, raising questions about product consistency and potency that may affect cardiovascular risk.

Massachusetts

Massachusetts established its medical marijuana program in 2012. The Cannabis Control Commission requires medical marijuana treatment centers to provide written materials on potential health risks, including cardiovascular effects, to all patients. Massachusetts General Hospital and Brigham and Women's Hospital have published patient education materials specifically addressing cannabis and heart health for Massachusetts medical marijuana patients.

New York

New York's medical marijuana program, which transitioned to adult-use legalization in 2021, initially prohibited smoking and required vaporization or edible forms—a policy partly based on cardiovascular and respiratory health concerns. The Office of Cannabis Management requires registered organizations to provide patient education materials that include cardiovascular risk information. New York mandates that healthcare practitioners complete a four-hour training course that includes cardiovascular effects of cannabis.

Ohio

Ohio's medical marijuana program includes chronic pain as a qualifying condition. The State Medical Board of Ohio requires physicians recommending cannabis to patients with cardiovascular disease to document discussions of risks and benefits. Ohio law requires product labels to include a general health warning but does not mandate specific cardiovascular warnings. The state's Patient and Caregiver Registry tracks adverse events, though cardiovascular event reporting remains limited.

Pennsylvania

Pennsylvania's medical marijuana program prohibits smoking, permitting only vaporization, oils, pills, topicals, and other non-combustible forms. This restriction was implemented partly due to cardiovascular and respiratory health concerns. The Pennsylvania Department of Health requires dispensaries to provide safety information including cardiovascular risks. Pennsylvania does not include cardiovascular conditions among its qualifying conditions.

What Experts Say

Medical experts express cautious concern about cardiovascular risks while acknowledging significant evidence gaps and potential therapeutic applications. Dr. Robert Page II, chair of the American Heart Association's 2024 scientific statement writing group, stated in a press release that the evidence suggests marijuana use, particularly smoking, may pose cardiovascular risks, but that more research is needed to understand the full scope of effects. According to the AHA statement, clinicians should advise patients that smoking or vaping any substance, including cannabis, is likely to be harmful to cardiovascular and overall health. Dr. Muthiah Vaduganathan, a cardiologist at Brigham and Women's Hospital, told the American College of Cardiology in 2025 that he routinely asks patients about cannabis use during cardiovascular risk assessments. According to Dr. Vaduganathan, the conversation focuses on delivery method, with strong recommendations against smoking and discussion of potential risks for patients with established cardiovascular disease. Dr. Deepak Cyril D'Souza, a psychiatry professor at Yale School of Medicine who studies cannabis, noted in a 2024 interview that the cardiovascular effects of cannabis are complex and likely depend on dose, frequency, delivery method, and individual cardiovascular risk factors. Dr. D'Souza emphasized that the increasing potency of cannabis products raises concerns about potential cardiovascular effects that may not have been apparent with lower-potency products used in earlier decades. Dr. Peter Grinspoon, a primary care physician at Massachusetts General Hospital and cannabis specialist, wrote in a 2025 Harvard Health Blog post that while cannabis likely poses some cardiovascular risk, particularly for individuals with existing heart disease, the magnitude of risk remains uncertain and must be weighed against potential benefits for conditions like chronic pain. Dr. Grinspoon recommended that patients with cardiovascular disease who choose to use cannabis should avoid smoking, use the lowest effective dose, and maintain close monitoring by their healthcare providers. The National Institute on Drug Abuse, in its 2025 research report on marijuana, stated that evidence suggests marijuana use may increase the risk of heart attack and stroke, particularly in individuals with existing cardiovascular risk factors. According to NIDA, more research is needed to understand whether specific cannabinoids, doses, or delivery methods might reduce cardiovascular risks.

What's Next

The coming 12-24 months will bring critical research findings, regulatory decisions, and clinical guideline updates that will shape understanding of cannabis and cardiovascular health. The NIH cardiovascular cannabis research initiative will begin enrolling participants in its first randomized controlled trials in late 2026. Results from a trial examining CBD for heart failure are expected in 2028, while observational studies tracking cardiovascular events in medical marijuana patients will produce interim findings in 2027. These studies will provide higher-quality evidence than currently available observational data. The DEA's proposed rescheduling of cannabis to Schedule III under the Controlled Substances Act could be finalized in late 2026 or early 2027, pending completion of the administrative law judge hearing process and final rule publication. Rescheduling would facilitate expanded cardiovascular research by reducing regulatory barriers, though cannabis would remain federally controlled. The American College of Cardiology plans to publish updated clinical guidance on cannabis and cardiovascular health in early 2027, incorporating recent research findings. The guidance will likely include more specific recommendations on patient screening, risk stratification, and counseling approaches. Several states are considering legislation that would require specific cardiovascular warnings on medical marijuana products. Connecticut introduced such legislation in 2026, though it had not advanced to a vote as of July 2026. Similar proposals are under consideration in Maryland and Minnesota. The FDA is evaluating whether to require cardiovascular safety studies for CBD products marketed as dietary supplements. The agency held a public hearing in March 2026 on CBD regulation and is expected to issue guidance on safety data requirements in late 2026 or 2027. Major medical cannabis operators are expanding cardiovascular research partnerships. Curaleaf's collaboration with Mount Sinai Hospital will publish initial findings from its observational study of cardiovascular outcomes in medical cannabis patients in early 2027. Green Thumb Industries announced in June 2026 that it would fund a cardiovascular safety study of low-dose THC products at Northwestern University. Insurance industry groups are developing standardized approaches to cannabis use in life insurance underwriting. The American Council of Life Insurers is expected to publish guidance in late 2026 on incorporating cannabis use into cardiovascular risk assessment for underwriting purposes. Professional medical societies are developing continuing education programs on cannabis and cardiovascular health. The American College of Cardiology launched an online module in May 2026 covering cardiovascular effects of cannabis, clinical assessment approaches, and patient counseling strategies.

Further Reading

• American Heart Association Scientific Statement: Medical Marijuana, Recreational Cannabis, and Cardiovascular Health (2024) - https://www.ahajournals.org/doi/10.1161/CIR.0000000000001233
• National Institute on Drug Abuse: Marijuana Research Report (2025) - https://nida.nih.gov/publications/research-reports/marijuana
• American College of Cardiology: Cannabis and Cardiovascular Disease Clinical Guidance (2025) - https://www.acc.org/latest-in-cardiology/articles/2025/cannabis-cardiovascular-disease
• JAMA Cardiology: Genetically Proxied Cannabis Use and Cardiovascular Disease Risk (2025) - https://jamanetwork.com/journals/jamacardiology
• 21 U.S.C. § 812: Controlled Substances Act Schedules - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13-subchapI-partB-sec812.htm
• Centers for Disease Control and Prevention: Heart Disease Facts - https://www.cdc.gov/heartdisease/facts.htm
• FDA: What You Need to Know About Cannabis Products - https://www.fda.gov/consumers/consumer-updates/what-you-need-know-about-products-containing-cannabis-or-cannabis-derived-compounds-including-cbd
• European Heart Journal: Cannabis Use and Risk of Cardiovascular Disease (2022) - https://academic.oup.com/eurheartj
• Journal of the American College of Cardiology: Marijuana Use and Cardiovascular Disease (2017) - https://www.jacc.org/
• Massachusetts General Hospital: Cannabis and Heart Health Patient Education Materials - https://www.massgeneral.org/